Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis

被引:42
|
作者
Aslani, Ferial [1 ]
Schuppe, Hans-Christian [2 ]
Guazzone, Vanesa A. [3 ]
Bhushan, Sudhanshu [1 ]
Wahle, Eva [1 ]
Lochnit, Guenter [4 ]
Lustig, Livia [3 ]
Meinhardt, Andreas [1 ]
Fijak, Monika [1 ]
机构
[1] Univ Giessen, Dept Anat & Cell Biol, D-35392 Giessen, Germany
[2] Univ Giessen, Dept Urol Pediat Urol & Androl, D-35392 Giessen, Germany
[3] Univ Buenos Aires, Fac Med, Inst Invest Biomed UBA CONICET, Buenos Aires, DF, Argentina
[4] Univ Giessen, Inst Biochem, Fac Med, D-35392 Giessen, Germany
关键词
testicular inflammation; experimental autoimmune orchitis; high mobility group box protein-1; receptor for advanced glycation end products; ethyl pyruvate; GLYCATION END-PRODUCTS; ETHYL PYRUVATE; RAT TESTIS; SIGNALING PATHWAYS; IMMUNE PRIVILEGE; GENE-EXPRESSION; LETHAL SEPSIS; SERTOLI-CELLS; HMGB1; RELEASE; RECEPTOR;
D O I
10.1093/humrep/deu320
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION: Does high mobility group box protein 1 (HMGB1) regulate inflammatory reactions in a rat model of experimental autoimmune orchitis (EAO)? SUMMARY ANSWER: HMGB1 appears to be involved in regulating inflammatory reactions in testes, as HMGB1 is translocated from testicular cells during the course of EAO and blocking its action by ethyl pyruvate (EP) reduces disease progression and spermatogenic damage. WHAT IS KNOWN ALREADY: Despite its immune privileged status, the human testis is prone to inflammatory lesions associated with male factor infertility. Accumulating evidence shows that HMGB1 plays an important role in onset and progression of autoimmune diseases. STUDY DESIGN, SIZE, DURATION: This is a cross sectional and longitudinal study involving Wistar male rats immunized with testicular homogenates to induce EAO50 (EAO50; n = 10) and 80 (EAO80; n = 10) days after first immunization. Control adjuvant animals received saline instead of testicular homogenate (n = 16). Untreated animals (n = 10) were also studied. An interventional study was performed to block the action of HMGB1 starting 20 days after first immunization in EAO animals and respective controls (n = 17). Ratswere treated i.p. with EP and the effect of EP treatment on testicular pathogenesis was evaluated 30 days later. Moreover, human testicular biopsies from infertile men with focal lymphocytic infiltrates (n = 7) and sections with intact spermatogenesis (n = 6) were probed with antibodies against HMGB1. PARTICIPANTS/MATERIALS, SETTING, METHODS: Testicular RNA and protein extracts from EAO animals, EAO animals treated with EP and relevant controls were used for analysis of cytokine expression by real-time RT-PCR and enzyme-linked immunosorbent assay. HMGB1 was co-localized on rat testicular cross sections with antibodies against testicular macrophages (TM), peritubular cells (PTC) and Sertoli cells (SC). Interaction of HMGB1 and its receptors (RAGE, TLR4) as well signaling pathways after HMGB1 stimulation were studied in isolated TM, PTC and SC by proximity ligation assay and western blot, respectively. Furthermore, HMGB1 immunofluorescence on human testicular biopsies was performed. MAIN RESULTS AND THE ROLE OF CHANCE: HMGB1 was translocated from the nuclei in EAO testes and testes of infertile men with impaired spermatogenesis and lymphocytic infiltrates. Elevated HMGB1 levels were observed during late phase of EAO. In testicular somatic cells HMGB1 receptors Toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE) were differentially expressed: HMGB1-TLR4 binding was predominant in TM, while HMGB1-RAGE interaction was prevalent in SC and PTC. In support, HMGB1 triggered extracellular signal regulated kinase (ERK) 1/2 and cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) activation in SC and PTC, while TM responded to HMGB1 stimulation with p38 mitogen-activated protein kinase (MAPK) and p65 nuclear factor Kappa B (NF-kappa B) phosphorylation followed by increased tumor necrosis factor a (TNF-alpha) and interleukin 6 (IL-6) mRNA levels. In vivo treatment of EAO animals with EP 20 days after induction of disease revealed beneficial effects, as documented by reduced disease progression and spermatogenic damage, lower macrophage numbers, as well as decreased concentrations of HMGB1 and IL-6 in the testis compared with EAO controls. LIMITATIONS, REASONS FOR CAUTION: The ability of HMGB1 to bind to a wide range of receptors makes it difficult to prevent its action by blockade of a specific receptor; therefore we applied EP, a drug preventing HMGB1 release from cells. Due to its mode of action EP decreases also the secretion of some other pro-inflammatory cytokines. Using isolated primary cells imposes limitations for cell transfection studies. As a compromise between purity and yield primary cells need to be isolated from animals of different age, which has to be considered when comparing their responses. WIDER IMPLICATIONS OF THE FINDINGS: HMGB1 could be a promising target in attenuating testicular damage caused by inflammatory reactions.
引用
收藏
页码:417 / 431
页数:15
相关论文
共 50 条
  • [31] Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis
    Sawa, Hidehiro
    Ueda, Takashi
    Takeyama, Yoshifumi
    Yasuda, Takeo
    Shinzeki, Makoto
    Nakajima, Takahiro
    Kuroda, Yoshikazu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (47) : 7666 - 7670
  • [32] Antagonism of Cerebral High Mobility Group Box 1 Ameliorates Dendritic Cell Dysfunction in Sepsis
    Ren, Chao
    Yao, Ren-qi
    Wang, Li-xue
    Li, Jun-cong
    Chen, Kun-wei
    Wu, Yao
    Dong, Ning
    Feng, Yong-wen
    Yao, Yong-ming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [33] Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway
    Li, Shu
    Li, Guangli
    Li, Xiaoyan
    Wu, Fan
    Li, Ling
    SKIN RESEARCH AND TECHNOLOGY, 2023, 29 (04)
  • [34] High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis
    Hoehne, Christopher
    Wenzel, Michael
    Angele, Barbara
    Hammerschmidt, Sven
    Haecker, Hans
    Klein, Matthias
    Bierhaus, Angelika
    Sperandio, Markus
    Pfister, Hans-Walter
    Koedel, Uwe
    BRAIN, 2013, 136 : 1746 - 1759
  • [35] High-mobility group box 1 serves as an inflammation driver of cardiovascular disease
    Wahid, Abdul
    Chen, Wei
    Wang, Xuewen
    Tang, Xiaohong
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [36] High Mobility Group Box 1 Neutralization in the Brain Prevents Inflammation, Sympathoexcitation and Hypertension
    Sriramula, Srinivas
    Nair, Anand R.
    Francis, Joseph
    FASEB JOURNAL, 2018, 32 (01):
  • [37] THERAPEUTIC TARGETING OF HIGH MOBILITY GROUP BOX 1 IN RAT MODELS OF PULMONARY HYPERTENSION
    Steinberg, Benjamin E.
    Hu, Yijie
    Hu, Xudong
    Tracey, Kevin J.
    Al-Abed, Yousef
    Goldenberg, Neil
    Kuebler, Wolfgang M.
    ANESTHESIA AND ANALGESIA, 2018, 126 (04): : 83 - 83
  • [38] Contributions of high mobility group box protein in experimental and clinical acute lung injury
    Ueno, H
    Matsuda, T
    Hashimoto, S
    Amaya, F
    Kitamura, Y
    Tanaka, M
    Kobayash, A
    Maruyama, I
    Yamada, S
    Hasegawa, N
    Soejima, J
    Koh, H
    Ishizaka, A
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (12) : 1310 - 1316
  • [39] Roles of high-mobility group box 1 in murine experimental colitis
    Yamasaki, Hiroshi
    Mitsuyama, Keiichi
    Masuda, Junya
    Kuwaki, Kotaro
    Takedatsu, Hidetoshi
    Sugiyama, Gen
    Yamada, Shingo
    Sata, Michio
    MOLECULAR MEDICINE REPORTS, 2009, 2 (01) : 23 - 27
  • [40] Can High Mobility Group Box 1 Protein Predict Ongoing Subclinical Inflammation in Patients With Familial Mediterranean Fever?
    Ozturk, Betul
    Baskin, Esra
    Gulleroglu, Kaan
    Avci, Begum
    Bayraktar, Nilufer
    Sahin, Feride Iffet
    JOURNAL OF DR BEHCET UZ CHILDRENS HOSPITAL, 2023, 13 (01): : 43 - 48